UBS Group’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

UBS Group’s Portfolio BCTXL Stock Details BCTXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.94K	Buy	+1,668	New	+$1.56K	﹤0.01%	10126

Other funds holding BCTXL

WAM

Warberg Asset Management Winnetka, Illinois $755M AUM 21.42% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

UBS Group's BCTXL Position: Q3 2026 in Review

UBS Group opened a new position in BriaCell Therapeutics Warrant (BCTXL) in Q3 2026: 1,668 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #10126 among its holdings.

3 funds tracked by Wall St. Rank hold BCTXL as of Q3 2026.

UBS Group held 1,668 shares of BriaCell Therapeutics Warrant worth $1.94K as of Q3 2026.
BriaCell Therapeutics Warrant was a new UBS Group position in Q3 2026.
BriaCell Therapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10126 holding.
3 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.